



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

February 7, 2023: 6:00 – 8:30 p.m.

- **Executive Session** **6:00 - 6:30**

- **Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**
(Public Comment Prior to Board Action)

- **DVHA Pharmacy Administration Updates** **6:40 - 6:45**

- **Chief Medical Officer Updates** **6:45 - 6:50**

- **Follow-up Items from Previous Meetings** **6:50 – 6:50**

- **RetroDUR/ProDUR** **6:50- 7:20**
 - Data presentation: Appropriate use of Asthma Controller Medications
 - Introduce: Use of Warfarin with Antibiotics

- **Clinical Update: Drug Reviews** **7:20-7:55**
(Public comment prior to Board action)
 - Biosimilar Drug Reviews**
 - None at this time.

 - Full New Drug Reviews**
(Any new drug reviews that also fall within the Therapeutic Class Review (TCR) will be discussed during the Therapeutic Class Review)
 - Amvuttra® (vutrisiran)
 - Enjaymo® (sutimlimab-jome)
 - Entadfi® (finasteride/tadalafil)
 - Hyftor® (sirolimus topical)
 - Korsuva® (difelikefalin)
 - Verkazia® (cyclosporine ophthalmic solution)
 - Vivjoa® (oteseconazole capsules)
 - Ztalmy® (ganaxolone)

- **New Managed Therapeutic Drug Classes** **7:55 -7:55**
 - None at this time

(Public comment prior to Board action)

- None at this time

▪ **Therapeutic Drug Classes – Periodic Review**

7:55 - 8:15

(Public comment prior to Board action)

- Gaucher Disease
- Hemophilia/Factor Deficiency
- Hereditary Angioedema
- Muscular Dystrophy
- Pancreatic Enzymes
- Platelet Stimulating Agents
- Prenatal Vitamins
- Psoriasis (Non- biologics) Oral & Topical (New Drugs Vtama® (tapinarof) and Zoryve® (roflumilast) included)

▪ **Review of Newly Developed/Revised Criteria**

8:15 - 8:25

(Public comment prior to Board action)

- Liquid Oral Nutritional Supplements
- Buprenorphine Safety Checklist

▪ **General Announcements**

8:25 – 8:30

- None at this time.

▪ **Adjourn**

8:30